ES2936394T3 - Métodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos oculares - Google Patents

Métodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos oculares Download PDF

Info

Publication number
ES2936394T3
ES2936394T3 ES16756227T ES16756227T ES2936394T3 ES 2936394 T3 ES2936394 T3 ES 2936394T3 ES 16756227 T ES16756227 T ES 16756227T ES 16756227 T ES16756227 T ES 16756227T ES 2936394 T3 ES2936394 T3 ES 2936394T3
Authority
ES
Spain
Prior art keywords
alpha
ophthalmic
dry eye
pharmaceutical formulation
brimonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16756227T
Other languages
English (en)
Spanish (es)
Inventor
Sandeep Jain
Uday Kompella
Shankar Musunuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana-Champaign
Ocugen Inc
University of Illinois System
Original Assignee
University of Illinois at Urbana-Champaign
Ocugen Inc
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana-Champaign, Ocugen Inc, University of Illinois System filed Critical University of Illinois at Urbana-Champaign
Application granted granted Critical
Publication of ES2936394T3 publication Critical patent/ES2936394T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16756227T 2015-02-24 2016-02-23 Métodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos oculares Active ES2936394T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119857P 2015-02-24 2015-02-24
PCT/US2016/019207 WO2016138049A1 (en) 2015-02-24 2016-02-23 Methods and compositions for treating dry eye disease and other eye disorders

Publications (1)

Publication Number Publication Date
ES2936394T3 true ES2936394T3 (es) 2023-03-16

Family

ID=56692824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16756227T Active ES2936394T3 (es) 2015-02-24 2016-02-23 Métodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos oculares

Country Status (12)

Country Link
US (1) US9597328B2 (enExample)
EP (1) EP3261620B1 (enExample)
JP (1) JP2018506570A (enExample)
KR (1) KR20170132725A (enExample)
CN (1) CN107427459A (enExample)
AU (1) AU2016222902A1 (enExample)
BR (1) BR112017017448A2 (enExample)
CA (1) CA2976120A1 (enExample)
ES (1) ES2936394T3 (enExample)
MX (1) MX2017010544A (enExample)
RU (1) RU2691412C2 (enExample)
WO (1) WO2016138049A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US11478437B2 (en) * 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
CA3080166A1 (en) * 2017-11-21 2019-05-31 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
CN119157876A (zh) * 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
WO2019189720A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
WO2019189721A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
WO2020047197A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
BR112022011067A2 (pt) * 2019-12-10 2022-08-23 Alcon Inc Insertos oculares poliméricos dissolvíveis com um polímero biodegradável
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
CN116710087A (zh) * 2020-11-23 2023-09-05 美国商业眼科医疗器械公司 用于治疗眼部病症的制剂和方法
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
EP4085891A1 (en) * 2021-05-05 2022-11-09 B. Braun Melsungen AG Dexmedetomidine-solution in a low-density polyethylene container
CN115645356A (zh) * 2022-11-21 2023-01-31 山东诺明康药物研究院有限公司 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用
WO2025174723A1 (en) * 2024-02-12 2025-08-21 Selagine Inc. Ophthalmic composition comprising cethromycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK3412U (sk) * 2002-07-01 2003-01-09 Unimed Pharma Spol Sro Očná inštalácia so zlepšenou stabilitou účinnej látky na báze brimomidínu
US20040088199A1 (en) * 2002-10-31 2004-05-06 Childress Allen B. Method of forming a business rule
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
JP2007528897A (ja) * 2004-03-12 2007-10-18 メルビ ホールディングス, エルエルシー 眼表面用の潤滑剤
WO2008011836A2 (es) * 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CN101352441A (zh) * 2007-07-27 2009-01-28 肖正连 一种酒石酸溴莫尼定眼用即型凝胶
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
KR101847669B1 (ko) * 2010-08-16 2018-05-24 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120093876A1 (en) * 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
EP2694048B1 (en) * 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid

Also Published As

Publication number Publication date
US9597328B2 (en) 2017-03-21
AU2016222902A1 (en) 2017-08-31
JP2018506570A (ja) 2018-03-08
RU2017129247A3 (enExample) 2019-03-25
EP3261620B1 (en) 2022-11-09
KR20170132725A (ko) 2017-12-04
RU2017129247A (ru) 2019-03-25
RU2691412C2 (ru) 2019-06-13
WO2016138049A1 (en) 2016-09-01
EP3261620A4 (en) 2018-10-31
BR112017017448A2 (pt) 2018-04-03
MX2017010544A (es) 2018-06-18
CN107427459A (zh) 2017-12-01
EP3261620A1 (en) 2018-01-03
US20160243116A1 (en) 2016-08-25
CA2976120A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
EP3261620B1 (en) Methods and compositions for treating dry eye disease and other eye disorders
JP7796783B2 (ja) 眼周囲分泌腺におけるまたは眼表面での異常な炎症を処置するための組成物および使用方法
US10555947B2 (en) Ophthalmic compositions and methods of use
US20080233053A1 (en) Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
EP2493474A2 (en) Methods and compositions for sustained delivery of drugs
US20190008920A1 (en) Ophthalmic compositions and methods of use
CN113473970A (zh) 用以治疗眼表疾病的眼科药物组合物和方法
KR20230058444A (ko) 코, 귀 및 다른 조직 감염 및/또는 염증을 치료하기 위한 조성물, 디바이스 및 방법
JP7397910B2 (ja) 一酸化窒素放出プロスタミドを含有する眼科用組成物
EP3727335A1 (en) Ocular drug delivery
US10751337B2 (en) Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders
US20110118226A1 (en) Transdermal pharmaceutical compositions comprising danazol
US20180221278A1 (en) Prsustained release opthalmic formuation and methods for using the same
CN101123948A (zh) 眼科用固体外用药剂
US9877964B2 (en) Methods and compositions for treating dry eye disease and other eye disorders
EP3843721A1 (en) Ophthalmic compositions and methods of use
EP4268827A1 (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
CA3115664C (en) Ophthalmic compositions and methods of use
HK40091801A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
CN116669705A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
HK40031931A (en) Oxymetazoline compositions and methods for treating ocular disorders
HK40018890A (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40018890B (en) Ophthalmic compositions containing a nitric oxide releasing prostamide